Rectal Cancer Presenting with Absceding Infection Due to Fusobacterium nucleatum

Zundler, Sebastian; Mardin, Christian Y.; Bertz, Simone; Vitali, Francesco; Strauß, Richard; Fürst, Julia; Neurath, Markus F.; Strobel, D

doi:10.3390/pathogens11101113

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many reports have confirmed that Fn exists near and in CRC cells (Su et al, 1992), Fn adheres to the cell surface (Engevik et al, 2021), this bacterium can reduce the body's immune regulation (Zundler et al, 2022), and stimulate the proliferation and metastasis of cancer cells (Kostic et al, 2013). Fn was added to the culture medium of CRC and observed by light microscopy as in Figure 1a, compared to the control group (A), the HT29 and HCT116 cells grew faster which co-culture with Fn, and had more cells in the same area, along with a more pronounced darker shade around the cells.…”

Section: Observation Of Co-culture Of Crc Cells With Fusobacterium Nu...mentioning

confidence: 94%

A new anti-colon cancer tumor pathway of Phenyllactic acid by reducing adhesion of Fusobacterium nucleatum

WANG

et al. 2023

Food Sci. Technol

View full text Add to dashboard Cite

The incidence of colorectal cancer (CRC) is increasing, with 1,931,590 new colorectal cancer patients worldwide in 2020. Fusobacterium nucleatum (Fn) has been widely reported as a harmful microorganism that promotes the development of CRC. Fn was found to enhance proliferation and metastasis of CRC cells by regulating cellular glucose metabolism and amino acid metabolism in trials. In a previous study, phenyl lactic acid (PLA), a natural metabolite of various probiotic bacteria, was found to have the ability to inhibit Fn as an organic acid. Therefore, further in-depth analysis of the mechanism of action of PLA in weakening Fn invasion into tumor cells provides a new therapeutic avenue for exacerbating CRC problems caused by intestinal pathogenic bacteria.

show abstract

Section: Observation Of Co-culture Of Crc Cells With Fusobacterium Nu...mentioning

confidence: 94%

A new anti-colon cancer tumor pathway of Phenyllactic acid by reducing adhesion of Fusobacterium nucleatum

WANG

et al. 2023

Food Sci. Technol

View full text Add to dashboard Cite

show abstract

“…The progression from precancerous adenomatous polyps to adenocarcinoma generally takes about 10 years [ 5 ], and is considered to be the consequence of host mutations that accumulate over time. Improved methods for detecting microorganisms and new insights into the human microbiome have led to a new perspective on several diseases, including CRC [ 6 , 7 , 8 ]. According to recent research, this cancer is linked with altered gut microbiota [ 9 ] and aided by the anaerobic gram-negative bacteria F. nucleatum [ 4 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…It is often linked to advanced disease, chemoresistance, distant metastases, and a poor prognosis [ 13 , 14 , 15 ]. Additional studies have demonstrated that F. nucleatum promotes carcinogenesis, changes lymphocyte infiltration of tumor-infiltrating lymphocytes, suppresses NK cell and tumor-infiltrating T cell death, and enhances resistance to chemotherapy in colon cancer [ 7 , 15 , 16 ]. Fusobacteria linked to CRC develops in the oral microbiome and reaches the colon through hematogenous rather than gastrointestinal routes.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Target Identification and Inhibitor Screening against Riboflavin Synthase of Colorectal Cancer Associated Fusobacterium nucleatum

Alturki

Mashraqi

Jalal

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) ranks third among all cancers in terms of prevalence. There is growing evidence that gut microbiota has a role in the development of colorectal cancer. Fusobacterium nucleatum is overrepresented in the gastrointestinal tract and tumor microenvironment of patients with CRC. This suggests the role of F. nucleatum as a potential risk factor in the development of CRC. Hence, we aimed to explore whole genomes of F. nucleatum strains related to CRC to predict potential therapeutic markers through a pan-genome integrated subtractive genomics approach. In the current study, we identified 538 proteins as essential for F. nucleatum survival, 209 non-homologous to a human host, and 12 as drug targets. Eventually, riboflavin synthase (RiS) was selected as a therapeutic target for further processing. Three different inhibitor libraries of lead-like natural products, i.e., cyanobactins (n = 237), streptomycins (n = 607), and marine bacterial secondary metabolites (n = 1226) were screened against it. After the structure-based study, three compounds, i.e., CMNPD3609 (−7.63) > Malyngamide V (−7.03) > ZINC06804365 (−7.01) were prioritized as potential inhibitors of F. nucleatum. Additionally, the stability and flexibility of these compounds bound to RiS were determined via a molecular dynamics simulation of 50 ns. Results revealed the stability of these compounds within the binding pocket, after 5 ns. ADMET profiling showed compounds as drug-like, non-permeable to the blood brain barrier, non-toxic, and HIA permeable. Pan-genomics mediated drug target identification and the virtual screening of inhibitors is the preliminary step towards inhibition of this pathogenic oncobacterium and we suggest mouse model experiments to validate our findings.

show abstract

Rectal Cancer Presenting with Absceding Infection Due to Fusobacterium nucleatum

Cited by 2 publications

References 11 publications

A new anti-colon cancer tumor pathway of Phenyllactic acid by reducing adhesion of Fusobacterium nucleatum

A new anti-colon cancer tumor pathway of Phenyllactic acid by reducing adhesion of Fusobacterium nucleatum

Therapeutic Target Identification and Inhibitor Screening against Riboflavin Synthase of Colorectal Cancer Associated Fusobacterium nucleatum

Contact Info

Product

Resources

About